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Rosacea is a common skin disease, accounting for 0.5-1 % of all cases seen in a dermatologic department [1]. Its nature remains largely obscure, but recent and old studies suggest a multifactorial etiology. The present review aims to give an account of recent findings 
rather than providing an exhaustive survey of the past literature. 
The reader is directed to the vast bibliography in the recent review 
by Wilkin [2]. 
CLINICAL FEATURES 
Rosacea is a multiphasic disease characterized by four stages of 
pathologic events: the sequence is not obligatory and few patients 
complete the course of the disease. In most cases its progress is 
arrested in the second stage. 
Frequent episodes of flushing (first stage) [3] are followed by 
persistent erythema (erythrosis) and telangiectases (second stage). 
Only a minority of the erythrotic patients develop papules and 
pustules (acne rosacea). Rhinophyma is the fourth and last stage, 
affecting only a restricted fringe of patients, usually men with 
erythrosis confined to the nose. 
The age of prevalence varies according to the stage considered. 
In a series of mine [4], the erythrotic patients were 38-40 years 
old and the papulo-pustular patients were 47-54 years old. Ro­
sacea is said to be more common among women, but this is true 
only for the first stages of the disease, possibly because women 
may seek cosmetologic advice more often than men. 
Flushing is an accessional redness of the face and frequently of 
the lateral aspects of the neck and the presternal area. In some 
cases also the shoulders are involved. Emotional stress, drinking 
alcohol and hot drinks, or even an ordinary meal trigger the 
flushing reactions. They differ from ordinary blushing in that 
these reactions are more frequently and easily induced. By no 
means is flushing an exclusive sign of rosacea. It occurs under 
many other circumstances, listed extensively by Wilkin [5]. 
Sometimes two such conditions coincide: menopausal hot flashes 
may accompany rosacea flushing and rosacea stigmata may occur 
in carcinoid syndrome [6,7]. 
Most of the flushers develop erythrosis and telangiectases on 
the same flushing areas. Telangiectases are usually fine on the 
cheeks and malar areas, whereas they tend to be coarse on the 
nose, especially on the pinnae. On rare occasions erythrosis is 
accompanied by lymphoedema [8]. On the lateral aspects of the 
neck and/or the mastoid area, the telangiectases are interfollicular 
and exceedingly fine (erythrosis interfollicularis colli; EIC) [9]. 
Under the chin, a rhomboidal area is constantly spared and is 
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neatly delimited by EIC. Whether this is due to a particular ar­
chitecture of the cutaneous vasculature or to the protection the 
chin offers against sunlight (vide infra) is unknown. Thorough 
reviews on skin vasculature [10] do not provide useful infor­
mation. 
Only a minority of people with erythrosis develop papules and 
pustules. Papules are either sparse or in crops, sometimes asym­
metric. but invariably more numerous than pustules. The neck 
is usually spared, except for a few isolated pustules. The bald 
scalp may be extensively involved [11]. 
In rare circumstances papules follow a chronic course and show 
a yellow-brown lupoid color that justifies old denominations such 
as "rosacea-like tuberculid of Lewandowsky" or "lupoid mil­
iaris. " I have never seen such lupoid papules below the chin, but 
they do occur in unusual areas such as the perioral zone and the 
bald scalp. 
Rhinophyma develops in a small number of erythrotic patients 
who flush and have coarse telangiectases frequently only on the 
nose. They rarely have pustules, and when they do the pustules 
are invariably isolated. Rhinophyma is a hypertrophy of both 
sebaceous glands and connective tissue along with a lymphede­
matous component. Mentophyma, otophyma, and zygophyma 
are very uncommon but devastating equivalents. 
Rosacea can be found in regions of the body other than the 
face and neck. Besides the bald scalp, the chest, back, and limbs 
may be affected [12]. Even the palms have been observed to show 
isolated pustules [4]. 
Eyes are quite often affected. Mild lesions include sties, chalazia, 
blepharitis, conjunctival hyperemia, superficial punctate kerato­
pathy, episcleritis, and iritis. Severe lesions consist of corneal 
neovascularization, scarring and thinning, or even corneal per­
foration. Blepharitis and conjunctival hyperemia are by far the 
most common occurrences. Sties and chalazia are often disre­
garded as rosacea stigmata, but rosacea has been found in 61 % 
of patients with chalazia [13]. Iritis and keratopathies are definitely 
rarer. The pH of tears from sufferers does not differ from that 
of control subjects [14]. Also keratoconjunctivitis sicca has been 
found to be significantly associated with ocular rosacea [15]. 
DIFFERENTIAL DIAGNOSIS 
Differential diagnosis is, in many cases, nothing mO.re than an 
academic exercise. Genuine clinical entities like rosacea have such 
precise features that diagnosis most often is not in doubt. None­
theless, conditions that are not genuine as clinical entities or that 
are genuine clinical entities in iatrogenic pathomorphosis or in 
concurrence with rosacea may confound diagnosticians. I shall 
discuss herein only those conditions, leaving aside alternatives 
that are unlikely ever to be taken into consideration. 
Hot flashes during menopause are frequently associated with 
rosacea flushing, occurring in the same period of life; flushing 
reactions due to drinking alcohol may coincide with or aggravate 
those occurring in genuine rosacea. 
The erythrotic stage of rosacea presents some difficulties in 
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diagnosis, the most common of which is corticosteroid rosacea 
[16]. Topical corticosteroids may change a number of facial der­
matoses to erythrotic rosacea. This is mostly the case of seborrheic 
dermatitis. Its confinement to the hairy scalp or to the retroaur­
icular and endoauricular regions may clarify the diagnosis. This 
is also the case of systemic lupus erythematosus, which lacks 
scarring and keratosis. Sometimes epidermal atrophy and mag­
nification of telangiectases due to corticosteroids make such a 
diagnosis extremely difficult. Direct immunofluorescence does 
not help as much in these cases, showing a linear deposition of 
immunoglobulins at the basal zone in much the same pattern as 
rosacea does [11,17-20]. A thorough investigation of systemic 
manifestations, and additional laboratory tests are needed. 
Haber's syndrome is one of the most curious examples of 
a critical quotation in dermatologic literature. After the original 
report by Sanderson and Wilson [21] no other genuine descrip­
tions of such "disease" have been published. The cases of Seiji 
and Otaki [22] and the one of Kikuchi [23] have been shown not 
to be Haber's syndrome but cases of Dowling-Degos disease 
[24-26]. I believe that Haber's syndrome is simply Dowling­
Degos disease with accompanying erythrotic rosacea. 
Papulo-pustular rosacea is quite easy t<;> diagnose. Some very 
rare perioral localization may be confused with perioral derma­
titis. Perioral dermatitis, which is quite rare now, shows vesico­
pustules rather than papulo-pustules, and prefers a younger age 
group than rosacea. Also, its unusual periocular distribution may 
be seldom confused with rosacea, which constantly spares that 
region. 
Demodicidosis does not seem to be as different from rosacea 
as Ayres [27] asserted, and the mite Demodex folliculomm is a 
common finding in papulo-pustular rosacea (vide infra). Only 
pruritus and fortnightly exacerbations would be differential cri­
teria [28]. 
Rosacea-like tuberculid of Lewandowsky belongs to the group 
of clinical entities the authenticity of which is discussed. It can 
not be differentiated from granulomatous rosacea. Their similar 
response to metronidazole suggests that they are probably the 
same disease. 
After their abrupt withdrawal, corticosteroids may change a 
number of diseases to a severe papulo-pustular rosacea. Atrophy 
of the skin, extension of the lesions beyond the areas usually 
involved by primitive rosacea, and its thick, grayish cretaceous 
scales, which incidentally are plenty of mites, are distinctive cri­
teria. On a background of "blushing and flushing" [16], corti­
costeroids have, in a few weeks, induced or facilitated the changes 
that "nature" spends years to provoke in true rosacea, namely, 
collagen and elastin damage, vascular changes, and Demodex pro­
liferation. 
Acne vulgaris is another of the classical differential diagnoses. 
The absence of comedos and the different age of prevalence would 
seem to distinguish it easily from rosacea, but this is by no means 
true. Even in adolescents, acne vulgaris may be associated with 
vascular changes that might be defined as "prerosacea" [16]. The 
condition is quite common and it is most important to recognize 
because of its extreme reactivity to topical treatments for acne. 
ETIOPATHOGENESIS 
Exhaustive reviews of the different factors that have been thought 
to play a role in rosacea have been done by others [1-3]. None­
theless, a crucial though obvious point is neglected in other re­
views, many of which merely enumerate such factors. 
As mentioned early in this essay, rosacea is a multiphasic disease 
and it seems likely that a different etiology is at work in each of 
its stages. In other words, factors inducing a functional disorder 
such as flushing are very likely to be different from factors that 
cause an organic pathology such as papulo-pustules. 
Psychogenic factors have been claimed to be of great impor­
tance. Wilkin has given an exhaustive account of the theoretical 
concepts and experimental results of a number of writers [2]. 
More recently, patients with rosacea have been studied with re-
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spect to their personality, and most of them revealed neuroses of 
the neurotic or psychasthenic type. In 91 %, a connection was 
suspected between their skin disease and stress situations [29]. 
Unfortunately, this belief is shared by the large majority of der­
matologic patients. 
The psychologic profile of the rosacea patient presents as an 
anxious, insecure, immature personality with crises of embar­
assment, guilt, and shame [30]. Because these traits are common 
in patients with other skin diseases such as urticaria and alopecia 
areata [30], it should be admitted that rosacea patients have a 
predisposition to facile blushing. However, the cause of predis­
position consists remains unknown. 
Although a familiarity may be found in some 30% of the pa­
tients, no significant association with HLA-A, HLA-B and -C 
phenotypes was found [31], discriminating between patients in 
the flushing-erythrotic stages and papulo-pustular patients. 
In any case, psychogenic factors are unlikely to play a role other 
than in inducing or facilitating flushes. Flushing is the earliest 
symptom in rosacea [32], but it does not have a peculiar mech­
anism of production [2]; in other words, flush in rosacea patients 
is not qualitatively different from other flushes, but shares their 
heterogeneous pathophysiology [33]. Different biochemical path­
ways are probably available, and each subject selects one or more 
of them on unknown bases. 
Gastrointestinal disturbances may also concur in inducing flush­
ing. Hypochloridria, gastritis, and abnormalities in jejunal mu­
cosa have been found and later denied [8,34]. A mild lipase se­
cretion deficiency has been reported [35]. In my experience, patients 
with rosacea show gross abnormalities in stomach, duodenum, 
or gall-bladder as frequently as the general population; approx­
imately 13%.  However, minor gastrointestinal problems are dif­
ficult to identify, and may be important in certain patients. Release 
of vasoactive intestinal pep tides may explain why the ingestion 
of ethanol facilitates flushing reactions in rosacea patients [33,36] 
of a type otherwise attributed to bradykinin [37] or to enkephalin 
and/or endorphin release [38]. In an unpublished study of mine, 
gastrin was found to be normal in flushing rosacea patients, whereas 
it was expected to be in excess because pentagastrin, its synthetic 
analog, had been shown to induce flushing [39]. 
There is no evidence that frequent, intense flushes alone lead 
to a loss of vascular tone resulting in the permanent vasodilation 
[5] typical of the erythrotic stage. In fact, Borrie [40,41] was 
unable to find any abnormality in testing facial vessels of rosacea 
patients with adrenaline, noradrenaline, histamine, and acethyl­
choline. I and my collaborators tested patients in all stages of 
rosacea and normal age-matched and sex-matched subjects by 
locally applying vasoactive agents such as ethylnicotinate, privine, 
and dimethyl sulfoxide (DMSO), and found that in rosacea facial 
vessels maintain their capacity for dilation and constriction. Fluids 
leak from them at a higher rate than they do in the general pop­
ulation. A significant fmding was a delayed clearance of the DMSO­
induced wheal in patients with erythrotic and papulo-pustular 
rosacea. These results suggest that the damage is in the dermis 
around the vessels as well as in their walls, and may coincide with 
the elastotic changes. In fact, a delayed clearance of the DMSO­
induced wheal has been also found on the sun-damaged nape 
without any rosacea-like lesion, in a clear parallel with the severity 
of its elastotic degeneration [42]. 
There is little doubt that sunlight combines with repeated flush­
ing to provoke erythrotic rosacea. The distribution of telangiec­
tases, including those of the EIC and of the presternal area, with 
the typical sparing of the submental region, and the benefits of 
the shadow projected by the chin; the prevalence of the disease 
in subjects with blue eyes and fair skin (1]; along with its peculiar 
onset in April through May [1] seem to be sufficient evidence. 
Ultraviolet radiation, however, has been said not to play an 
essential role in rosacea. When tested with a high-pressure mer­
cury lamp, only 20 patients with rosacea versus 14 control subjects 
were found to have an increased reaction to UV. This difference 
was not statistically significant [43]. Many years ago, also Brod-
58s REBORA 
thagen [44] and Sobye [1] found no abnormal reaction to light in 
rosacea patients, but Brodthagen's failure in inducing rosacea at 
the sites of light testing can only be regarded as naive. 
Other radiation may damage collagen and elastin fibers. In­
frared rays have been poorly studied thus far. In my experience, 
as in Sobye's [1], erythrotic rosacea is fairly common in people 
occupationally exposed to heat. The worst rosaceas I have ever 
seen were in steel-workers. 
UV A may also be important, able as it is to reach the dermis, 
and the synergy of infrared and UV radiations should not be 
disregarded [45]. 
Repeated flushing reactions and sunlight overexposure may 
explain erythrosis and even facial "phyma" [7], but something 
more is needed to turn a disease that, up to this stage, is largely 
functional (or in any case involves little organic damage) into an 
inflammatory disease like papulo-pustular or granulomatous ro­
sacea. 
Both cell-mediated and humoral immunity play an important 
role. Studies with anti-human T cell monoclonal antibodies showed 
that the perifollicular lymphoid infiltrate is made ofT cells, with 
a prevalence of the helper-inducer subset [46]. Other studies, on 
the contrary, found very few T cells amid histiocytes and IgM­
bearing cells [47]. The importance of the humoral immunity is 
suggested also by the difficulty of sensitizing rosacea patients with 
dinitrochlorobenzene with respect to the general population [20], 
and by the finding of anticollagen immunoglobulins at the der­
moepidermal junction [11,17-20] and/or in the derrnis [19,20]. 
In addition, a number of antinuclear antibodies of various types 
were detected in the blood, either free [20] or bound to lymphoid 
cells [19]. 
Contrasting evidence is offered by the activity of metronidazole 
in papulo-pustular rosacea. Its mechanism remains unknown (vide 
infra) but, as proven in other granulomatous disorders, both ex­
perimental [48] and clinical [49], metronidazole may act as a se­
lective suppressor of some aspects of the cell-mediated immunity. 
The antigens the humoral immunity is directed against are 
partially known, and include light-altered collagen and nuclear 
components, along with the mite Demodex folliculorum. 
Anticollagen antibodies have been found in both involved and 
uninvolved sun-exposed skin, suggesting that light degeneration 
of collagen (or possibly elastic fibers) is a prerequisite for mount­
ing the immune response [19,20]. Also, the positivity of the basal 
zone may mean an activity towards sun-damaged collagen IV 
[19]. 
Nuclei of the epidermal, dermal, endothelial, and eccrine ductal 
cells in involved and uninvolved skin, both in sun-exposed and 
sun-protected areas, were found to be the target of antibodies, 
mainly IgM and IgE, eluted from circulating lymphoid cells [19]. 
Circulating antinuclear IgM were also found in an unexpected 
percentage of patients [20]. 
These findings had suggested that antibodies could react to UV­
altered DNA, but pyrimidine dimers, induced by UVC radiation, 
were not found [50]. 
Antibodies (lgG) directed to Demodex folliculorum were also 
detected in rosacea skin [19]. Demodex-specific antibodies were 
also shown in 22% of rosacea patients and in goats and rabbits 
that had been sensitized with small amounts of demodectic (D 
caprae) antigen. Frequent cross-reactions were observed with an­
tigens of house-dust mites and Tyrophagus putrescentiae [51]. 
The mechanism of production of rhinophyma is unknown. Its 
occurrence in subjects who flush almost exclusively on the nose, 
the fact that carcinoid syndrome induces facial "phyma," and 
even visceral adenomatosis [52], after intense and repeated flushes 
[7] suggest that rhinophyma may be accounted for by flushing 
itself or by the vasoactive substances responsible for it. 
In conclusion, the available evidence, both clinical and exper­
imental, suggests that rosacea patients are particularly prone to 
physiologic flushing reactions induced by psychosomatic and, 
possibly, gastrointestinal stimuli. In these subjects a chronic rel­
ative overexposure to light and/or to heat produces telangiectases 
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through degenerative changes of the perivascular (and possibly 
vascular) collagen and elastic tissues. In a minority of these pa­
tients, a number of antigens, including Demodex folliculorum and 
altered collagen (and possibly elastic fibers), generate an immune 
response leading to the inflammatory changes that clinically ap­
pear as papules, pustules, and lupoid nodules. 
TREATMENT 
Flushing may be relieved by all drugs that are used for migraine, 
but its severity rarely makes any medication necessary. 
Clonidine, for example, has been successfully used in migraine 
and menopausal hot flashes, but its efficacy in rosacea is discussed 
[53,54]. In addition, its withdrawal may induce dangerous re­
bound effects on blood pressure that make its use in rosacea 
flushers unadvisable. Atenolol, 50 mg/day, is well tolerated and 
virtually free from side effects, but its efficacy is inconsistent. 
Naloxone has been found to be effective, and the use of an oral 
opiate antagonist has been suggested for prevention [38]. Other 
drugs, such as methysergide, HI and H2 antagonists, chlorprom­
azine, indomethacin, and ibuprofen [55], are useless or poorly 
tolerated. 
There is no treatment that grants good results in erythrosis. 
Conventional local vasoconstrictors have no effect. Sunscreens 
should be prescribed, and any exposure to heat sources should 
be thoroughly avoided. 
Three facts should be taken into consideration while treating 
patients with papulo-pustular rosacea. First, their facial skin is 
extremely sensitive to topical agents, which are seldom tolerated. 
Second, as mentioned before, many patients have been on topical 
corticosteroids for a long time and should be warned that, after 
steroid withdrawal, any treatment may initially worsen the dis­
ease. Worsening is actually due to a rebound effect, but it may 
induce the patient to abandon the treatment (and his doctor). 
Third, the success of placebos is usually great, accounting for as 
many as 45% of successes [56]. 
Oral treatment consists of tetracyclines, metronidazole, cypro­
terone acetate [57], and 13-cis-retinoic acid [58]. 
In my experience, metronidazole is by far the most effective 
treatment. I use 500 mg/day for 20 days, and it is rare that the 
patients are not cured after that time. 
Tetracyclines are a second choice treatment because they are 
less active [59] and relapses are more frequent [60]. 
Cyproterone acetate (10 mg) in an oral contraceptive has been 
found effective in a very small sample of patients [57]. 
Inflammatory changes and even telangiectases should disappear 
within 8 weeks of treatment with 0.05-1.0 mg/kg body weight 
13-cis-retinoic acid [58]. 
Side effects of metronidazole include gastrointestinal distur­
bances that resolve spontaneously and, much more rarely, a cu­
taneous erythematous rash. Peripheral neuropathies mainly occur 
after patients have received a cumulative dose of>30 g [61]. The 
disulfiram-like effect requires abstinence from alcohol. Long-term 
problems may arise from its effect on the genetic material of 
somatic cells. The frequency of chromosome aberrations in cul­
tured lymphocytes from patients on high-dose .and long-term 
metronidazole was found to be higher than in control subjects 
[62]. Metronidazole treatment in schedules longer than 30 days 
[60] should therefore be avoided or confined to the cases that did 
not respond to other treatments [63] and, obviously, excluded in 
pregnancy. 
Phototoxicity of tetracyclines may be a serious inconvenience, 
rosacea being prevalent in spring. Due to its teratogenic properties 
13-cis-retinoic acid cannot be given in fertile women. 
The mechanism by which metronidazole acts is unknown. Its 
possible direct activity on Demodex folliculorum seems unlikely. 
The mite has been shown to survive in as much as 1 mg/rnl 
metronidazole [64]. It may be that one or more of its metabolites 
are the aetual effective agents. Metronidazole's major urinary 
product, the 2-hydroxymethyl derivative, is up to 10 times more 
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active as an antibacterial agent than metronidazole itself [65] and 
its possible antiparasitic activity should be studied. 
Besides the suppression of the cell-mediated immunity, me­
tronidazole may act against anaerobes, including Propionibacterium 
ames, modifying the intestinal flora from which active metabolites 
might be produced. 
Understanding the mechanism of action of tetracyclines and 
other antibiotics such as chloramphenicol, ampicillin, and eryth­
romycin could provide an important etiologic clue. They may 
act by suppressing skin flora, but bacteria do not seem to play 
any role in rosacea; they may reduce the number of mites [66], 
possibly through a reduction of bacteria the mites live upon; some 
of the antibiotics reduce leukocyte migration and phagocytosis 
[67]. 
Cyproterone acetate and 13-cis-retinoic acid presumably work 
by suppressing sebum production [68]. Since sebaceous activity 
has long ago proved not to play any role in rosacea [69], the 
decreased sebum production may affect the bacterial or parasitic 
survival in the skin. It is to be noted, however, that Demodex 
folliculorum derives its diet from the proteins rather than from the 
lipids of sebum [70]. 
Local treatment should be cautiously tried, 10% sulfur cream 
[71], 2% erythromycin in ethanol solution [72], and 1 % me­
tronidazole cream [73] have been found to be as effective as oral 
antibiotics. 
My thanks to Marcella Guarrera, Pharo D. for her help ill the preparation of 
this essay. 
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